Completed
Low Dose Oral Interferon Alfa-n3 Treatment in ARC Patients
What is being tested
Interferon alfa-n3
Drug
Who is being recruted
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+19 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorInterferon Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
The study has been extended to offer 52 weeks of maintenance therapy after the 10 weeks of the placebo controlled period are concluded successfully.
Principal SponsorInterferon Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
45 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections
Criteria
4 inclusion criteria required to participate
Allowed prior use of Zidovudine (AZT) at a dose = or < 600 mg/day at least 90 days prior to study entry
Been receiving a dose of = or < 600 mg/day of zidovudine (AZT) at least 90 days prior to study entry IF they are currently taking AZT
Diagnosis of AIDS related complex (ARC)
Given written informed consent
15 exclusion criteria prevent from participating
Absolute CD4 count of < 100 or > 350 cells/mm3
Active IV drug abuse within 3 months of study entry
Any disease or disorder listed in Patient Exclusion Co-existing Conditions
Development of antibodies to interferon during prior interferon therapy that occurred > 3 months prior to study entry
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center